• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by AngioDynamics Inc.

    2/13/25 4:32:31 PM ET
    $ANGO
    Medical/Dental Instruments
    Health Care
    Get the next $ANGO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    ANGIODYNAMICS INC

    (Name of Issuer)


    AngioDynamics Inc.

    (Title of Class of Securities)


    03475V101

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03475V101


    1Names of Reporting Persons

    SYSTEMATIC FINANCIAL MANAGEMENT LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,484,876.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,521,066.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,521,066.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ANGIODYNAMICS INC
    (b)Address of issuer's principal executive offices:

    14 PLAZA DRIVE, 14 PLAZA DRIVE, LATHAM, NEW YORK, 12110.
    Item 2. 
    (a)Name of person filing:

    Michele Egeberg Managing Director, Compliance
    (b)Address or principal business office or, if none, residence:

    300 Frank W. Burr Boulevard, 7th Floor Teaneck, NJ 07666
    (c)Citizenship:

    United States of America
    (d)Title of class of securities:

    AngioDynamics Inc.
    (e)CUSIP No.:

    03475V101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,521,066
    (b)Percent of class:

    6.15%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,484,876

     (ii) Shared power to vote or to direct the vote:

    0.0

     (iii) Sole power to dispose or to direct the disposition of:

    2,521,066

     (iv) Shared power to dispose or to direct the disposition of:

    0.0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SYSTEMATIC FINANCIAL MANAGEMENT LP
     
    Signature:Michele Egeberg
    Name/Title:Managing Director, Compliance
    Date:02/13/2025
    Get the next $ANGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANGO

    DatePrice TargetRatingAnalyst
    4/5/2024$12.00Perform → Outperform
    Oppenheimer
    9/25/2023$19.00Buy
    H.C. Wainwright
    4/17/2023$14.00 → $13.00Strong Buy → Outperform
    Raymond James
    10/15/2021$28.00 → $37.00Hold → Buy
    Canaccord Genuity
    8/20/2021Perform
    Oppenheimer
    7/14/2021$24.00 → $28.00Hold
    Canaccord Genuity
    7/9/2021$27.00 → $32.00Strong Buy
    Raymond James
    More analyst ratings

    $ANGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights   Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sales $72.0 million 9.2% Med Tech Net Sales $31.3 million 22.2% Med Device Net Sales $40.7 million 0.9% GAAP gross margin of 54.0% GAAP loss per share of $(0.11) Adjusted loss per shar

      4/2/25 6:30:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics to Host Virtual Cardiovascular Investor Event

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual Cardiovascular Investor Event Date: Wednesday, April 2, 2025 Time: 9:00am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=c

      3/31/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products. Fiscal 2025 Third Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate

      3/19/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by AngioDynamics Inc.

      SCHEDULE 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)

      4/14/25 4:11:01 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by AngioDynamics Inc.

      10-Q - ANGIODYNAMICS INC (0001275187) (Filer)

      4/2/25 2:14:31 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ANGIODYNAMICS INC (0001275187) (Filer)

      4/2/25 9:40:35 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AngioDynamics Inc.

      SC 13G - ANGIODYNAMICS INC (0001275187) (Subject)

      5/30/24 4:25:33 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AngioDynamics Inc. (Amendment)

      SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)

      2/13/24 4:58:53 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AngioDynamics Inc. (Amendment)

      SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)

      2/9/24 9:58:57 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AngioDynamics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded AngioDynamics from Perform to Outperform and set a new price target of $12.00

      4/5/24 7:36:59 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • H.C. Wainwright initiated coverage on AngioDynamics with a new price target

      H.C. Wainwright initiated coverage of AngioDynamics with a rating of Buy and set a new price target of $19.00

      9/25/23 8:09:50 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics downgraded by Raymond James with a new price target

      Raymond James downgraded AngioDynamics from Strong Buy to Outperform and set a new price target of $13.00 from $14.00 previously

      4/17/23 7:20:48 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP Quality and Regulatory Nighan Warren Jr bought $5,285 worth of shares (868 units at $6.09), increasing direct ownership by 2% to 45,877 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      10/10/24 3:22:57 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • EVP and CFO Trowbridge Stephen A bought $9,962 worth of shares (1,700 units at $5.86), increasing direct ownership by 0.99% to 172,711 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      10/8/24 6:27:36 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • President and CEO Clemmer James C bought $120,600 worth of shares (20,000 units at $6.03), increasing direct ownership by 3% to 681,582 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      10/8/24 4:32:02 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Financials

    Live finance-specific insights

    See more

    $ANGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights   Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sales $72.0 million 9.2% Med Tech Net Sales $31.3 million 22.2% Med Device Net Sales $40.7 million 0.9% GAAP gross margin of 54.0% GAAP loss per share of $(0.11) Adjusted loss per shar

      4/2/25 6:30:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics to Host Virtual Cardiovascular Investor Event

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual Cardiovascular Investor Event Date: Wednesday, April 2, 2025 Time: 9:00am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=c

      3/31/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products. Fiscal 2025 Third Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate

      3/19/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SVP Quality and Regulatory Nighan Warren Jr sold $49,979 worth of shares (4,060 units at $12.31), decreasing direct ownership by 9% to 41,817 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      1/17/25 4:05:54 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SVP, Chief Legal Officer Weiss Lawrence T was granted 52,697 shares (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      12/4/24 9:33:45 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Weiss Lawrence T

      3 - ANGIODYNAMICS INC (0001275187) (Issuer)

      12/4/24 9:29:59 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    Leadership Updates

    Live Leadership Updates

    See more
    • AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

      AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company's Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company's Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. "Ms

      7/24/23 4:01:00 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • PAVmed Appoints Shaun O'Neil as Chief Operating Officer

      PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities

      2/24/22 8:25:00 AM ET
      $ANGO
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

      VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an

      6/1/21 4:01:00 PM ET
      $SCL
      $RCEL
      $ANGO
      Package Goods/Cosmetics
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care